DRKS00021507已完成4 期
A randomized, controlled, investigator-blinded, multicenter, single-cross-over interventional pilot study to investigate the effect of virtual reality enhanced education on rheumatoid arthritis for healthcare professionals on knowledge, illness perception and empathy toward patients with rheumatoid arthritis: the VENTURE trial - VENTURE-Trial
Justus Liebig Universität Gießen, Campus Kerckhoff, Abt. für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin0 个研究点目标入组 40 人开始时间: 2020年8月25日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Healthcare Professional working in Rheumatology
排除标准
- •Key Exclusion Criteria. Please see study protocol for a complete list.
- •- a diagnosis of a rheumatic disease
- •- neurologic disease prohibiting the use of virtual reality
- •- any disease prohiniting the use of virtual reality
研究者
相似试验
进行中（未招募）
不适用
An randomized, controlled, investigator-blinded, prospective, mono-centre study to evaluate the efficacy of fosfomycin versus meropenem in patients with complicated urinary tract infections - urosepsis/fosfo vs. meropenemThis study will primarily address the question of the efficacy of intravenous fosfomycin 4 g b.i.d. in the therapy of patients presenting with complicated urinary tract infection. These data will be compared to meropenem administered intravenously at a dose of 2 g b.i.d.MedDRA version: 9.1Level: LLTClassification code 10046571Term: Urinary tract infectionEUCTR2007-005112-37-ATMedizinische Universität Wien, Abteilung für Interne Medizin I240
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855BronchiectasisEUCTR2019-002840-26-GBovartis Pharma AG72
进行中（未招募）
1 期
Study of LIK066 in overweight and obese women with polycystic ovary syndromepolycystic ovary syndromeMedDRA version: 20.0Level: LLTClassification code 10036050Term: Polycystic ovarySystem Organ Class: 100000004872EUCTR2017-001373-16-DEovartis Pharma AG29
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855BronchiectasisEUCTR2019-002840-26-DEovartis Pharma AG72
进行中（未招募）
1 期
Study to assess the efficacy and safety of CJM112 in patients with inadequately controlled severe asthmaInadequately controlled moderate to severe asthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-000205-21-DKovartis Pharma AG110